[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-diseases":670},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,62,0,25,[9,48,60,82,110,141,174,213,239,259,291,314,337,357,393,419,442,472,491,509,539,569,594,622,651],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053705",false,"NCT06615973","Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke","Understanding Stroke Outcomes: Stroke Resilience, Infarct Burden, and Long-Term Cognition","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Adults aged 18 or older.\n* Previous participant in the Natural History of Stroke with an interpretable baseline MRI scan, NIHSS measured at baseline or discharge, and admission diagnosis of ischemic stroke.\n* Fluent in English or Spanish\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this\n\nstudy:\n\n-Modified Rankin Scale (mRS) = 6 at any follow-up (usually up to 90 days) in the Natural History of Stroke study (mRS = 6 indicates the participant is dead).","ALL","18 Years","99 Years",{"count":20,"type":21},450,"ESTIMATED","OBSERVATIONAL","Background:\n\nStroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive strokes have mental impairment or dementia. Medical factors, such as the severity of the stroke, affect whether a person will have mental impairment afterward. But social factors, such as education and ethnicity, seem to play a role as well. Researchers want to learn more about how social and lifestyle factors affect a person s chances of maintaining mental functions after a stroke.\n\nObjective:\n\nTo better understand how social and lifestyle factors affect the risk of mental impairment after a stroke.\n\nEligibility:\n\nPeople aged 18 years and older who had a stroke and a brain scan while they were enrolled in NIH Study 01N0007 (Natural History of Stroke Study).\n\nDesign:\n\nParticipants will have 1 study visit, by telephone. The call will last about 45 minutes. Participants will talk about their health since their stroke. They will answer questions about themselves. Topics will include:\n\n* Their race\n* Education\n* Ethnicity\n* Employment\n* Marital status\n* Residence address\n* Recent health history\n* Medical insurance\n\nThey will have tests of their memory, attention, and language skills. They will repeat numbers and words forward and backward.\n\nResearchers will look at the data and imaging scans collected during participant s enrollment in NIH Study 01N0007. This data will include:\n\n* The hospital that first saw the participant at the time of their stroke.\n* The type of imaging that was first used then.\n* The primary diagnosis at admission.\n* Other medical details.",[25,26,27,28],"Stroke","Brain Disease","Vascular Diseases","Cerebrovascular Disorder",[25,30,31,32,33,34],"Social Determinants of Health","Cognition","cerebrovascular health","Magnetic Resonance Imaging (MRI)","vascular health","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":21},"2026-07-16",{"date":43,"type":21},"2027-02-01",{"name":45,"class":46},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":49,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":51,"keywords":52,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":47},"100563423",{"count":20,"type":21},[25,26,27,28],[25,30,31,32,33,34],"2026-07-01",{"date":55,"type":39},"2026-07-02",{"date":57,"type":21},"2026-07-07",{"date":43,"type":21},{"name":45,"class":46},{"id":61,"slug":4,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":16,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100558565","NCT06552767","Thrombosis and Inflammation in Vessels Initiative (TIVI)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Age \\>= 5 years at the time of consent\n* Ability of subject or Legally Authorized Representative (LAR) as applicable to understand and the willingness to sign a written informed consent document\n\nIn addition, the following cohort-specific inclusion criteria apply:\n\nAffected Subjects:\n\n-Known or possible thrombotic, immune, or vascular disorder after review of the subject s medical records and\u002For discussion of medical history\n\nRelatives of Affected Subjects:\n\n-Being a relative of an affected subject\n\nUnrelated Healthy Controls:\n\n-In good general health as evidenced by medical history\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n-Any condition that in the opinion of the Investigator would warrant exclusion\n\nUnrelated Healthy Controls:\n\n* Unrelated healthy volunteers who decline to have blood drawn and\u002For tissue studies or who do not consent to have samples stored for future research\n* Cognitively impaired individuals",true,"5 Years","100 Years",{"count":69,"type":21},1000,"Background:\n\nDiseases related to the immune system, blood clots, and blood vessels can affect every part of the body. These diseases are now known to be interrelated: People who have strokes, blood clots in their legs, or autoimmune disease, for example, are at greater risk of complications in the heart, brain, and other organs. Researchers want to learn more about how these diseases start, how they change over time, and how they affect different organs.\n\nObjective:\n\nTo learn more about how inflammation and diseases of the blood vessels start and how they change over time.\n\nEligibility:\n\nPeople aged 5 years and older with a disease related to blood clots, the immune system, or blood vessels. Healthy relatives of people with these diseases and unrelated healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have a baseline visit: They will provide a medical history, physical exam and blood test. All other tests and procedures are optional; these may be spread over more than 1 day:\n\nTests of heart and lung function.\n\nFill in a family tree form.\n\nImaging scans\n\nTreadmill or bike stress tests and a 6-minute walk test.\n\nTests of blood pressure and the flow of blood through vessels.\n\nPhotos of the face and body.\n\nEye exams, with photos taken of the retina.\n\nSaliva and urine samples.\n\nBiopsies (tissues samples) of the skin and fat.\n\nTests of thinking and mental function.\n\nEvaluations by other medical specialists.\n\nParticipants may opt to return for repeat testing for up to 90 months (7.5 years).\n\nSome visits may be done by telehealth.",[72,27],"Cardiovascular Diseases",[74],"Vascular",{"date":55,"type":39},{"date":77,"type":39},"2024-11-22",{"date":79,"type":21},"2034-01-30",{"name":81,"class":46},"National Heart, Lung, and Blood Institute (NHLBI)",{"id":83,"slug":4,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100601857","NCT07115953","Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension","Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)","SWYFT","Inclusion Criteria:\n\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)\n4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery anatomy\n2. Individual has undergone prior renal denervation\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73m2\n6. Individual has one or more episode(s) of orthostatic hypotension\n7. Individual is pregnant, nursing or planning to become pregnant\n8. Individual has documented primary pulmonary hypertension\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%",{"count":90,"type":21},130,"INTERVENTIONAL",[93],"NA","The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.",[96,27,72,97,98],"Hypertension","Chronic Kidney Diseases","Diabetes Mellitus","2026-06-29",{"date":101,"type":39},"2026-06-30",{"date":103,"type":39},"2025-09-22",{"date":105,"type":21},"2029-12-31",{"name":107,"class":108},"Medtronic Vascular","INDUSTRY",21,{"id":111,"slug":4,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":91,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100585805","NCT06907147","SPYRAL GEMINI Pilot Study","Global Pilot Study of rEnal and Hepatic coMbINed denervatIon in Subjects With Uncontrolled Hypertension With and Without High Cardiovascular Risk","SPYRAL GEMINI","Inclusion Criteria:\n\nAll Subjects (both cohorts):\n\n1. ≥18 and ≤80 years of age.\n2. Diagnosed with HTN and has a baseline office SBP ≥150 mmHg and \\\u003C180 mmHg and an office DBP ≥ 90 mmHg.\n3. 24-hour average SBP ≥140 mmHg and \\\u003C170 mmHg measured by ABPM at Baseline.\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery OR common hepatic artery anatomy.\n2. Prior renal or hepatic denervation.\n3. History of NYHA Class III or IV heart failure within 6 months of screening visit.\n4. Stroke or transient ischemic attack (TIA) within 6 months of screening visit or any history of stroke leading to permanent disability.\n5. Documented Type 1 diabetes or use of insulin within 6 months.\n6. Secondary cause of hypertension.\n7. Documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement.\n8. Estimated glomerular filtration rate (eGFR) of \\\u003C40\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Primary pulmonary arterial hypertension.\n11. History or evidence of active \u002F suspected chronic liver or biliary disease.\n12. Current or chronic pancreatitis.","80 Years",{"count":119,"type":21},175,[93],"The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.",[96,27,72,97,98],[124,125,126,127,128,96,72,27,129,130,131],"Renal Insufficiency","Chronic Disease","Disease Attributes","Pathologic Processes","Kidney Diseases","Denervation","Renal Denervation","Hepatic Denervation","2026-06-22",{"date":134,"type":39},"2026-06-24",{"date":136,"type":39},"2025-05-01",{"date":138,"type":21},"2029-12-22",{"name":107,"class":108},18,{"id":142,"slug":4,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":91,"phases":150,"briefSummary":151,"conditions":152,"keywords":160,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":47},"100644087","NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.",{"count":149,"type":21},706,[93],"MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[153,154,72,27,155,156,157,158,25,159],"Nervous System Diseases","Cerebrovascular Disorders","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage","Cerebral Hemorrhage, Hypertensive","Hemorrhagic Stroke, Intracerebral",[161,162,163],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","NOT_YET_RECRUITING","2026-06-18",{"date":134,"type":39},{"date":168,"type":21},"2026-06",{"date":170,"type":21},"2028-07",{"name":172,"class":173},"Xuanwu Hospital, Beijing","OTHER",{"id":175,"slug":4,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":181,"targetDuration":4,"studyType":91,"phases":183,"briefSummary":184,"conditions":185,"keywords":199,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":47},"100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)",{"count":182,"type":21},1859,[93],"The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[186,187,72,188,189,27,190,191,192,193,194,195,196,197,198],"Coronary Disease","Heart Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[200,201,202,203],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2026-06-15",{"date":206,"type":39},"2026-06-17",{"date":208,"type":39},"2026-06-11",{"date":210,"type":21},"2033-06",{"name":212,"class":108},"Teleflex",{"id":214,"slug":4,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":4,"leadSponsor":237,"locationsCount":238},"100058931","NCT00009243","Natural History of Stroke: Cause and Development","Evaluation, Pathogenesis, and Treatment of Patients With or at Risk for Cerebrovascular Disease (A Natural History\u002FDisease Pathogenesis Protocol)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Aged \\>=18\n2. Presented to participating study site (ED, ICU, or inpatient unit) with or at risk of acute stroke, TIA, or other disturbances of cerebrovascular circulation\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Subjects with contraindication to MRI scanning will be excluded from any testing which involves the use of MRI. The contraindications include subjects with the following devices or conditions:\n\n   * Central nervous system aneurysm clips\n   * Implanted neural stimulator\n   * Implanted cardiac pacemaker or defibrillator\n   * Cochlear implant\n   * Ocular foreign body (e.g. metal shavings)\n   * Insulin pump\n   * Metal shrapnel or bullet\n   * Any implanted device that is incompatible with MRI\n\n   Subjects with a condition precluding entry in the scanner (e.g. morbid obesity, Claustrophobia, etc.) will not be included in the MRI portion of this study.\n2. Pregnancy","120 Years",{"count":221,"type":21},4000,"The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies.\n\nPatients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland.\n\nThe study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following:\n\n* Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests.\n* Electrocardiogram (EKG) (heart tracing)-electrodes placed on the chest wall detect the heartbeat and heart rhythm.\n* Computed tomography (CT) scan of the head-specialized X-rays are used to obtain images of the brain.\n* Magnetic resonance imaging (MRI) of the brain-a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels.\n* Transcranial Doppler (TCD)-sound waves are used to image the arteries of the brain and neck.\n* Echocardiogram-sound waves are used to image the heart and evaluate heart function.\n\nPatients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and\u002For 12 months, when some of these tests may be repeated to assess changes over time",[26,224,225,28,27],"Ischemic Attack, Transient","Cerebrovascular Accident",[25,227,228,229,230,231],"Natural History","MRI (Magnetic Resonance Imaging)","Magnetic Resonance Imaging","Acute Stroke","TIA","2026-06-13",{"date":234,"type":39},"2026-06-16",{"date":236,"type":39},"2001-01-26",{"name":45,"class":46},3,{"id":240,"slug":4,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":91,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":47},"100449578","NCT05134311","Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies","3D-US","Inclusion Criteria:\n\n* Age 18 years of age or older\n* Suspected vascular insufficiency that requires ultrasound evaluation\n* Subject is able to sign a consent form\n* Scheduled ultrasound testing at the wound center to evaluate vasculature\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Subject is not scheduled to have ultrasound testing at the wound center\n* Subject is unable to or refuses to consent to participate",{"count":246,"type":21},270,[93],"The ability to have a visual aid to depict areas of vascular disease that are affecting the patient's health can help in patient comprehension of the problem. This comprehension can lead to better understanding of the issue and increase patient compliance to treatment. The hand drawn sketch produced by the ultrasound technologist provides an inadequate visualization of the vascular insufficiency that is causing the patient's symptoms.\n\nPIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging. This system will provide a low cost and reproducible imaging solution that will be an effective educational tool for people with vascular disease.",[250,27,251],"PAD - Peripheral Arterial Disease","Wounds",{"date":204,"type":39},{"date":254,"type":39},"2025-07-01",{"date":256,"type":21},"2028-09-01",{"name":258,"class":173},"Northwell Health",{"id":260,"slug":4,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":265,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":91,"phases":269,"briefSummary":271,"conditions":272,"keywords":281,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":47},"100537733","NCT06281665","Treatment With Aspirin After Preeclampsia: TAP Trial","TAP","Inclusion Criteria:\n\n* Postpartum individuals ≥18 years old\n* Preeclampsia diagnosis\n\nExclusion Criteria:\n\n* Fetal anomaly\n* Multiple gestation\n* Pre-pregnancy hypertension\n* Allergy or contraindication to low-dose aspirin\n* Pre-pregnancy diabetes","FEMALE","55 Years",{"count":268,"type":21},60,[270],"PHASE4","The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and\u002For microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.",[273,274,96,275,276,72,277,278,27,279,280],"Hypertensive Disorder of Pregnancy","Pre-Eclampsia","Eclampsia","Gestational Hypertension","Toxemia","Pregnancy Complications","Hypertension, Pregnancy Induced","Hypertension;Pre-Eclamptic",[96],"2026-06-03",{"date":284,"type":39},"2026-06-04",{"date":286,"type":39},"2024-05-29",{"date":288,"type":21},"2027-09-01",{"name":290,"class":173},"Malamo Countouris",{"id":292,"slug":4,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":91,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":47},"100592207","NCT06990425","CLOSM Trial: Groin Closure Using Layered Option for Suture Material","CLOSM","Inclusion Criteria:\n\n* All patients \\> 18 years who undergo ELECTIVE vascular surgery that would require groin incisions\n* Patients with to undergo ELECTIVE bilateral groin incisions will be matched to receive closure with PDS in one groin and Vicryl in the other groin\n\nExclusion Criteria:\n\n1. Age 17 or younger\n2. Prisoners\n3. Pregnant patients\n4. Emergent cases\n5. Active groin infection prior to intervention\n6. History of prior surgical groin access (re-operative groin)\n7. Groin closure after extracorporeal membrane oxygenation (ECMO)",{"count":298,"type":21},259,[93],"This is a randomized controlled trial comparing groin closure after vascular intervention with Vicryl suture versus PDS (polydioxanone) suture. This will be a single center trail performed at CCF main campus. Patients will be enrolled in a prospective fashion and will be randomized 1:1 to either PDS or Vicryl closure. Patients undergoing bilateral groin exposure will be randomized to receive both closure types to either groin.",[27],[303,304,305],"surgical site complication","vascular surgery","wound healing","2026-06-01",{"date":282,"type":39},{"date":309,"type":39},"2025-03-27",{"date":311,"type":21},"2027-12-31",{"name":313,"class":173},"The Cleveland Clinic",{"id":315,"slug":4,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":91,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":336},"100627491","NCT07449325","Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","SERRA-I US","Inclusion criteria\n\n1. Older than 18 years of age.\n2. Left ventricular ejection fraction (LVEF) is greater than or equal to 25% within the 12 months before the index procedure. Note: The LVEF must be reassessed after any intervening myocardial infarction. The most recent LVEF assessment is used as the qualifying test for subjects with multiple assessments\n3. Greater than or equal to 30 days of persistent symptomatic coronary microvascular dysfunction (angina pectoris, or equivalent symptoms) (classified as CCS Grade II - IV angina, or NYHA Class 2 or 3 equivalent non-anginal functional impairment) despite optimal medical therapy, as determined by Investigator and confirmed by the Central Screening Committee. Note: Optimal medical management is defined as at least 2 anti-anginal medications or maximally tolerated medical therapy if less than 2 anti-anginal medications.\n4. CFR\\\u003C2.5 measured with continuous thermodilution within 30 days of index procedure. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators. RCA measurements are not permitted for this study.\n\n   Note: CFR should be measured in LAD or LCX if LAD is not feasible. RCA measurements are not permitted for this study\n5. Sustained angina (or equivalent symptoms) reported for at least 2 weeks leading up to the index procedure, as reported via the ORBITA-app.\n6. Willing and able to sign informed consent.\n7. Willing to comply with the specified follow-up evaluations.\n\n   Procedural Angiographic\u002FHemodynamic Inclusion Criteria:\n\n   The following will be assessed during the index procedure to confirm eligibility before an attempt at implantation. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators if not yet obtained in the prior 30 days (see inclusion criteria 4).\n8. Mean right atrial pressure ≤15 mmHg.\n9. The CS anatomy is suitable for implantation at the Investigator's discretion\n\nExclusion Criteria\n\n1. Significant obstructive epicardial disease (greater than 50% diameter stenosis) that can be treated with PCI or CABG as determined by Investigator and confirmed by the Central Screening Committee.\n2. Recent (less than 30 days before index procedure) troponin or CKMB positive acute coronary syndrome (NSTEMI or STEMI) with evidence of ischemia.\n\n   Note: subjects with an elevated troponin or CKMB without acute coronary syndrome may still be considered eligible.\n3. Extra-coronary contributory causes of angina- e.g., untreated hyperthyroidism, anemia (Hgb less than 9 g\u002FdL), uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg despite medications), atrial fibrillation with a rapid ventricular response (consistently greater than 100 bpm despite medications) or other tachyarrhythmia, severe aortic stenosis, decompensated heart failure, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or asymmetric septal hypertrophy (concentric left ventricular hypertrophy is not an exclusion criterion).\n4. NYHA class IV or decompensated HF or hospitalization due to HF during the 90 days before the index procedure.\n5. Life-threatening rhythm disorders or any rhythm disorders that would require cardiac resynchronization therapy or lead placement in the coronary sinus.\n6. Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second (FEV1) of less than 1.0L or need for home daytime oxygen or regular oral steroids.\n7. Severe valvular heart disease (any valve).\n8. Moderate (TAPSE\\\u003C12) or severe RV dysfunction (TAPSE\\\u003C8) by echocardiography.\n9. A pacemaker electrode\u002Flead is present in the coronary sinus.\n10. Recent implantation of a new pacemaker or defibrillator leads with any electrode in the right atrium within 90 days of the index procedure.\n11. Chronic severe renal failure (estimated eGFR less than 30 mL\u002Fmin\u002F1.73m2 or equivalent) or subjects on chronic dialysis.\n12. Known allergy to titanium, nickel, platinum, tungsten, or known inability to tolerate contrast medium\n13. Any clinical condition that might interfere with the trial protocol or the subject's ability to be compliant with the trial protocol (e.g., active alcohol or illicit substance use, cognitive decline).\n14. Currently enrolled in another investigational device or drug trial that has not reached its primary endpoint or might clinically interfere with the current trial endpoints or procedures.\n15. Pregnant or planning pregnancy within the next 12 months (females of reproductive potential must have a negative pregnancy test within 7 days of the procedure).\n16. Part of a vulnerable population who, in the investigator's judgment, cannot give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances, or lack of autonomy.\n17. Inability to tolerate dual antiplatelet therapy for 6 months if not on a chronic oral anticoagulant, or inability to tolerate a P2Y12 inhibitor for at least 6 months if on a chronic oral anticoagulant.\n18. Comorbidities limiting life expectancy to less than one year.\n19. Currently hospitalized for definite or suspected COVID-19.",{"count":322,"type":21},30,[93],"VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.",[198,196,187,72,27,326],"Microvascular Angina","2026-05-14",{"date":329,"type":39},"2026-05-15",{"date":331,"type":21},"2026-04",{"date":333,"type":21},"2027-12",{"name":335,"class":108},"VahatiCor, Inc.",2,{"id":338,"slug":4,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":91,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":355,"locationsCount":47},"100559941","NCT06570681","Video Call Assisted Assessment of Acute Stroke","Video Call Assisted Assessment of Acute Stroke in Addition to Stroke Scales in a Prehospital Setting: A Cluster Randomised Controlled Trial","Inclusion Criteria:\n\n* Suspected stroke within 24 hours from onset (confirmed with Prehospital Stroke 1 decision tool)\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Suspected stroke more than 24 hours ago\n* In-hospital stroke or private transport to hospital\n* Unconsciousness defined as Glasgow Coma Score (GCS) ≤ 8 (as they cannot be rated)",{"count":344,"type":21},512,[93],"This study aims to investigate whether a live stream video between the on-call neurologist and the emergency medical technicians can increase feasibility and performance of symptom-based prehospital stroke scales.",[25,154,348,153,27,349],"Brain Diseases","Central Nervous System Diseases","2026-05-11",{"date":327,"type":39},{"date":353,"type":39},"2024-05-27",{"date":282,"type":21},{"name":356,"class":173},"University of Southern Denmark",{"id":358,"slug":4,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":16,"minAge":363,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":91,"phases":367,"briefSummary":368,"conditions":369,"keywords":375,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":47},"100562453","NCT06603363","Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","INTENSE","Inclusion Criteria:\n\n* patients referred for coronary computed tomography angiography (CTA)\n* females aged 45-75 years and males aged 40-75 years\n* presence of at least mild coronary atherosclerosis (luminal stenosis \\>25%, with at least one partially calcified or non-calcified plaque)\n* statin-naive patients\n* ability to understand and provide written informed consent\n* FFR-CT value ≥0.75, indicating the absence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* contraindications to coronary CTA\n* current or prior treatment with statins or other lipid-lowering agents (e.g., ezetimibe)\n* age below 45 years in females or below 40 years in males\n* age above 75 years in both sexes\n* pregnancy or breastfeeding\n* type 1 or type 2 diabetes mellitus\n* history of coronary stent implantation or coronary artery bypass grafting\n* history of myocardial infarction\n* ≥70% luminal stenosis in the proximal left anterior descending artery (LAD), or ≥50% stenosis in the left main (LM) coronary artery\n* FFR-CT value \\\u003C0.75 in any coronary artery\n* elevated serum alanine aminotransferase (ALT) levels (\\>3× the upper limit of normal)\n* elevated serum creatine kinase (CK) levels (\\>3× the upper limit of normal)\n* LDL cholesterol level \\>5 mmol\u002FL\n* renal failure or significantly impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* ongoing oncological treatment\n* active liver disease\n* known hypersensitivity to any excipients of the investigational product\n* concomitant treatment with the combination of sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir\n* concomitant treatment with cyclosporine\n* women of childbearing potential not using adequate contraception\n* presence of myopathy","45 Years","75 Years",{"count":366,"type":21},140,[93],"INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to coronary CT angiography due to stable chest pain, followed for 24 months by using a photon-counting detector CT (PCD-CT).\n\nINTENSE Trial aims 1) to assess the effect of short-term intensified statin therapy on coronary anatomy and physiology using PCD-CT and 2) to determine the impact of short-term, intensified statin therapy on coronary plaque morphology and hemodynamics to identify statin responder and non-responder patients in addition to testing the hypothesis of \"plaque memory\" after the 24-month follow-up period.",[195,370,371,372,373,187,72,188,27,374],"Atherosclerotic Plaque","Coronary Computed Tomography Angiography","Statin Therapy","Multidetector Computed Tomography","Hyperlipidemia",[376,377,378,379,380,381,382,383],"coronary artery disease","stable chest pain","intermediate pretest probability","explanatory randomised controlled trial","coronary computed tomography angiography","photon-counting detector CT","atherosclerotic plaque","statin therapy","2026-05-08",{"date":386,"type":39},"2026-05-13",{"date":388,"type":39},"2025-05-28",{"date":390,"type":21},"2028-12-15",{"name":392,"class":173},"Prof. Maurovich-Horvat Pál",{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":400,"targetDuration":66,"studyType":22,"phases":4,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100538934","NCT06297291","Global Paradise System US Post Approval Study","The Global Paradise® System US Post Approval Study (US GPS)","US GPS","Inclusion Criteria:\n\n* Signed and dated study informed consent\n* Documented history of hypertension\n* Documented history of prior or current antihypertensive medication(s)\n* Mean seated office systolic BP at screening ≥ 140 mmHg\n* Mean pre-procedure home systolic BP of ≥ 135 mmHg\n* Estimated glomerular filtration rate (eGFR) of ≥30 mL\u002Fmin\u002Fm2\n\nRADIANCE CAP patients must provide signed and dated informed consent for inclusion in long-term follow-up. No other criteria are required for inclusion.\n\nExclusion Criteria:\n\nPatients who meet the following will be excluded from participation:\n\n* Patient lacks appropriate renal anatomy for any treatment with the Paradise Catheter\n* Patient under the age of 18 years old at the time of consent\n* Patient is pregnant\n* Patients with transplanted kidney\n* Presence of abnormal kidney (or secreting adrenal) tumors\n\nTo confirm eligibility for treatment with the Paradise System, the following contraindications listed in the IFU may be determined at the time of procedure prior to treatment:\n\n* Renal arteries with diameter \\\u003C 3mm and \\> 8mm\n* Renal artery with fibromuscular dysplasia (FMD)\n* Stented renal artery\n* Renal artery aneurysm\n* Renal artery diameter stenosis \\>30%\n* Iliac\u002Ffemoral artery stenosis precluding insertion of the Paradise Catheter",{"count":69,"type":21},"The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.",[96,72,27],[404,405,406,407,130,408],"Blood Pressure","Uncontrolled Hypertension","Essential Hypertension","Resistant Hypertension","Ultrasound Renal Denervation","2026-05-01",{"date":411,"type":39},"2026-05-07",{"date":413,"type":39},"2024-06-28",{"date":415,"type":21},"2031-07",{"name":417,"class":108},"ReCor Medical, Inc.",39,{"id":420,"slug":4,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":426,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":91,"phases":430,"briefSummary":431,"conditions":432,"keywords":433,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":336},"100594014","NCT07013929","Spyral InSight Study","Spyral InSight Early Clinical Feasibility Study","Spyral InSight","Inclusion Criteria:\n\n1. 20 - 70 years of age\n2. Office SBP ≥150 mmHg and \\\u003C180 mmHg and DBP ≥90 mmHg\n3. Individual is prescribed with one, two, or three antihypertensive medication classes\n4. 24-hour ABPM average of SBP ≥135 and \\\u003C170 mmHg at Baseline\n\nExclusion Criteria:\n\n1. Prior renal denervation.\n2. Individual lacks appropriate renal artery Anatomy\n3. Has a renal artery stent\n4. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C60 mL\u002Fmin\u002F1.73m2\n5. Individual is taking SGLT2 inhibitors or GLP-1 agonists\n6. Individual requires chronic oxygen support or mechanical ventilation\n7. Primary pulmonary hypertension.\n8. Secondary cause of hypertension\n9. Pregnant, nursing or planning to become pregnant during the study.\n10. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n11. Individual is currently taking anti-mineralocorticoid drugs.","20 Years","70 Years",{"count":429,"type":21},19,[93],"The purpose of the Spyral InSight Early Clinical Feasibility Study is to characterize the physiological response to renal nerve stimulation (RNS) in humans prior to and post renal denervation.",[96,27,72],[96,72,27,129,130],"2026-04-30",{"date":436,"type":39},"2026-05-04",{"date":438,"type":39},"2025-06-09",{"date":440,"type":21},"2027-07-01",{"name":107,"class":108},{"id":443,"slug":4,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":265,"minAge":449,"maxAge":427,"enrollmentInfo":450,"targetDuration":452,"studyType":22,"phases":4,"briefSummary":453,"conditions":454,"keywords":455,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":47},"100530456","NCT06187012","Hypertension Explored in Long-term Postpartum Follow-up in Later Life","Hypertension Explored in Long-term Postpartum Follow-up in Later Life (HELPFUL)","HELPFUL","Inclusion Criteria:\n\n* Inclusion Criteria\n\n  * Participant is willing and able to give informed consent for participation in the study\n  * Female who had a pregnancy 10 to 25 years prior\n  * Able (in the investigator's opinion) and willing to comply with all study requirements.\n  * Adequate understanding of verbal and written English\n\nExclusion Criteria:\n\n* The participant may not enter the study if ANY of the following apply:\n\n  * Over 10 weeks pregnant during the course of the study\n  * Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status\n  * Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study\n\nFor exclusion of MRI component only:\n\n• Unsuitable for MRI based on the responses to the MRI screening form. The participant may still be included in other parts of the study.","30 Years",{"count":451,"type":21},200,"40 Years","The purpose of this study is to understand more about why women who have had hypertensive pregnancies may be at increased risk of high blood pressure and why these women are often at increased risk of heart and blood vessel disease later in life.",[96,72,154,27],[456,457,458,459,460,461,462],"Hypertensive pregnancy","Older adults","Pre-eclampsia","Gestational hypertension","Cardiovascular risk","Disease progression","Longitudinal","2026-04-28",{"date":465,"type":39},"2026-04-29",{"date":467,"type":39},"2023-03-23",{"date":469,"type":21},"2042-11-01",{"name":471,"class":173},"University of Oxford",{"id":473,"slug":4,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":477,"targetDuration":4,"studyType":91,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":489,"locationsCount":4},"100485229","NCT05598359","TA-65 and Aging Associated Microvascular Dysfunction","Inclusion Criteria:\n\n* Healthy Adults 18 - 35 and 65+ years of age\n* Subjects with clinical diagnosis of CAD\n\nExclusion criteria will include:\n\n* 36-64 years of age without clinical diagnosis of CAD\n* Self-reported habitual vigorous exercise (\\>20 min, 3 times per week, 1 yr)\n* Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)\n* Heart Failure\n* Renal Impairment\n* \\>3 Pre-existing Cardiovascular Risk Factors (healthy groups only)\n* Type 1 or type 2 diabetes\n* Uncontrolled hypertension\n* Current tobacco use or within last 6 months\n* BMI \\> 35\n* Hyperlipidemia\n* Hypercholesterolemia\n* Use of anti-coagulant drugs\n* Use of anti-platelet drugs\n* Erectile dysfunction medication in the past 6 months\n* Use of topical\u002Fnon-topical steroids in last 6 months\n* Hormone replacement therapy (Post-Menopause or Gender Reassignment)\n* History of retinopathy\n* Documented neuromuscular disorders\n* Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)\n* Pregnancy (young female subjects)\n* Allergy to lidocaine\n* Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months\n* Active COVID-19 or within the past 3 months",{"count":478,"type":21},180,[93],"The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.",[482,483,27],"Telomere Shortening","Aging","2026-04-27",{"date":409,"type":39},{"date":487,"type":21},"2027-01-01",{"date":105,"type":21},{"name":490,"class":173},"Medical College of Wisconsin",{"id":492,"slug":4,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":47},"100606366","NCT07174622","Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation","Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data","SPYRAL CARE","Inclusion Criteria:\n\n* Enrolled in a Medicare plan\n* Diagnosis of uncontrolled hypertension\n* On a stable regimen of antihypertensive therapy\n\nExclusion Criteria:\n\n* A prior RDN procedure\n* Diagnosis of secondary hypertension\n* Any condition for which RDN is contraindicated",{"count":69,"type":21},"This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.",[96,72,27],"2026-04-21",{"date":503,"type":39},"2026-04-22",{"date":505,"type":39},"2025-10-28",{"date":507,"type":21},"2029-06",{"name":107,"class":108},{"id":510,"slug":4,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":91,"phases":518,"briefSummary":520,"conditions":521,"keywords":526,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":47},"100618558","NCT07333183","A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD","An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria:\n\n* Participants willing and able to provide informed consent\n* Participants on inhaled treprostinil\n* Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:\n\n  1. Idiopathic interstitial pneumonia (IIP)\n  2. Chronic hypersensitivity pneumonitis\n  3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \\\u003C 70% of predicted\n* Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).\n* Ability to perform 6MWD ≥100 meters.\n\nExclusion Criteria:\n\n* Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).\n* Exacerbation of underlying lung disease within 28 days prior to randomization.\n* Initiation of pulmonary rehabilitation within 28 days prior to randomization.\n* Receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n* History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.\n* Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.\n\nNote: Other inclusion and exclusion criteria may apply.","85 Years",{"count":517,"type":21},20,[519],"PHASE2","This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.",[522,523,524,27,72,525],"Pulmonary Hypertension","Interstitial Lung Disease (ILD)","Lung Diseases","Fibrosis",[527,528,529,530],"PH","ILD","6 Minute Walk Test","mosliciguat","2026-04-18",{"date":503,"type":39},{"date":534,"type":39},"2025-12-23",{"date":536,"type":21},"2028-01",{"name":538,"class":108},"Pulmovant, Inc.",{"id":540,"slug":4,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":91,"phases":548,"briefSummary":549,"conditions":550,"keywords":554,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":568},"100607166","NCT07185022","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion","a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","RESCUE MeVO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA)\n* The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction)\n* Intra-arterial thrombolysis was administered within the following time windows:\n\n  1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA;\n  2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \\\u003C30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Pre-stroke mRS ≥ 2\n* Secondary MeVO or severe stenosis caused by endovascular therapy\n* Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders\n* Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory\n* Platelet count \\\u003C100 × 10⁹\u002FL, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \\>3.0\n* Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Presence of arteriovenous malformations or brain tumors with mass effect\n* Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months\n* Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL)\n* Patients with known allergy to thrombolytic agents or their excipients\n* Patients with known allergy to iodinated contrast agents or other established contraindications\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason",{"count":547,"type":21},282,[93],"Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.",[25,154,348,153,27,551,552,553],"Ischemic Stroke","Infarction","Medium Vessel Occlusion",[555,556,25,557,558],"Ischemic stroke","Medium vessel occlusion","Intra-arterial thrombolysis","Severe stenosis","2026-04-13",{"date":561,"type":39},"2026-04-16",{"date":563,"type":39},"2026-01-06",{"date":565,"type":21},"2030-05-01",{"name":567,"class":173},"The Second Hospital of Anhui Medical University",6,{"id":570,"slug":4,"hasResults":11,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":65,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":91,"phases":577,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":593},"100536957","NCT06271577","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II (STLEUISII)","STLEUISII","Inclusion Criteria:\n\n* Male or female \\> 18 years of age.\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.\n* Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.\n\nExclusion Criteria:\n\n* Inability or refusal of the patient and\u002For the patient's legally acceptable representative to provide written informed consent for any reason.\n* Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and\u002For compromise the quality of the clinical trial.",{"count":69,"type":21},[93],"AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).\n\nRecently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.",[580,581,196,187,72,27,582,583],"Myocardial Infarction","Ischemia","Heart Attack","Heart Failure","2026-04-08",{"date":586,"type":39},"2026-04-09",{"date":588,"type":39},"2024-03-12",{"date":590,"type":21},"2027-03",{"name":592,"class":108},"AliveCor",4,{"id":595,"slug":4,"hasResults":11,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":91,"phases":603,"briefSummary":604,"conditions":605,"keywords":609,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":621},"100407377","NCT04584632","The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery","A Clinical Evaluation of the Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery","Efemoral I","Inclusion Criteria:\n\n* Symptomatic peripheral vascular occlusive disease (Rutherford-Becker Clinical Category 2-4)\n* Patient with life expectancy \\>36 months\n* Females of childbearing potential must have negative pregnancy test\n* Patient is able to provide informed consent\n* Patient agrees to undergo all protocol-required follow-up examinations and requirements at the investigational site.\n* Patient must be able to take antiplatelet and\u002For anticoagulant agents as prescribed\n* Single de novo native disease segment of the superficial femoral artery (SFA) or P1 popliteal segment\n* Reference vessel diameter ≥5.5 mm and ≤6.5 mm\n* Target lesion length ≤90 mm\n* Target lesion with ≥50% DS\n* Inflow artery and popliteal artery free from flow-limiting lesion (DS \\\u003C50%)\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C9.0 g\u002FdL\n* WBC \\\u003C3,000 cells\u002Fmm3\n* Platelet count \\\u003C80,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3\n* Acute or chronic renal dysfunction with creatinine \\>2.5 mg\u002Fdl (176 µmol\u002FL)\n* Severe liver impairment as defined by total bilirubin ≥3 mg\u002Fdl or two times increase over the normal level of SGOT or SGPT\n* A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticagrelor or sirolimus, or with contrast sensitivity for which the patient cannot be adequately pre-medicated\n* Patient requires a planned procedure that would necessitate discontinuation of antiplatelet therapy\n* Patient is unable to walk\n* Patient has undergone a percutaneous vascular intervention \\\u003C30 days prior to the planned index procedure\n* Patient is maintained on chronic hemodialysis\n* Patient has uncontrolled diabetes mellitus (HbA1c ≥7.0%).\n* Patient has had a myocardial infarction within the previous 30 days of the planned index procedure\n* Patient has had a stroke within the previous 30 days of the planned index procedure and\u002For has deficits from a prior stroke that limits the patient's ability to walk\n* Patient has unstable angina defined as rest angina with ECG changes\n* Patient has a local groin or acute systemic infection that has not been treated successfully or is currently under treatment\n* Patient has acute thrombophlebitis, deep vein thrombosis or chronic venous insufficiency in either extremity\n* Patient has other medical illnesses (e.g., cancer, congestive cardiomyopathy, etc.) that may cause the patient to be non-compliant with protocol requirements, confound the data interpretation or will prevent completion of all required follow up assessments through 36 months\n* Patient is currently participating in an investigational drug, biologic, or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints\n* Patient has ischemic or neuropathic ulcers on either foot\n* Patient has undergone minor or major amputation of either lower extremity\n* Patient is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent\n* Target extremity with an angiographically significant (\\>50% DS) lesion located distal to the target lesion that requires treatment at the time of the index procedure or by a staged procedure\n* Acute arterial ischemia of the target extremity\n* Target extremity has been previously treated with open surgical revascularization (bypass or endarterectomy)\n* Target vessel has been previously treated with stent, laser, atherectomy, surgical bypass, or endarterectomy\n* Total occlusion (100% DS) of the ipsilateral inflow artery\n* Angiographic evidence of thrombus in the target vessel\n* The target lesion requires treatment with a device other than percutaneous transluminal balloon angioplasty (PTA) \\[e.g., orbital atherectomy, directional atherectomy, excimer laser, rotational atherectomy, cryoplasty, etc.\\]\n* Target lesion is within or adjacent to an aneurysm\n* Patient has angiographic evidence of thromboembolism or atheroembolism from treatment of an ipsilateral iliac lesion or from crossing or pre-dilating the target lesion\n* Target lesion has moderate-to-severe calcification\n* Target lesion with \\> 30% residual stenosis following pre-dilatation",{"count":602,"type":21},100,[93],"To evaluate the safety and performance of the EVSS in patients with symptomatic peripheral vascular disease from stenosis or occlusion of the femoropopliteal artery",[606,27,607,608],"Peripheral Arterial Disease","Stenosis","Femoropopliteal Stenosis",[610,611],"Peripheral Artery Disease","Bioresorbable","2026-03-23",{"date":614,"type":39},"2026-03-25",{"date":616,"type":39},"2020-09-22",{"date":618,"type":21},"2030-03",{"name":620,"class":108},"Efemoral Medical, Inc.",8,{"id":623,"slug":4,"hasResults":11,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":515,"enrollmentInfo":629,"targetDuration":4,"studyType":91,"phases":631,"briefSummary":632,"conditions":633,"keywords":637,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":4},"100609422","NCT07214376","A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","The PULSE-LHD","Inclusion Criteria:\n\n1. Subject is ≥18 and ≤85 years of age\n2. Subject is diagnosed with chronic HF due to left-sided heart disease for at least 6 months prior to screening (regardless of LVEF), and remains symptomatic despite maximally tolerated class I GDMT for left heart failure and CRT as appropriate per US or EU guidelines according to region of enrollment\n3. Subject is clinically stable, defined as:\n\n   * No hospitalizations for heart failure for at least 1 month; no major changes in societal guideline-recommended class I oral GDMT for left heart failure for at least 1 month; no CRT or ICD implant in the prior 3 months; and no anticipated major changes in any HF-GDMT (other than possibly diuretic dose) or planned cardiac rhythm management device implantation after the procedure\n   * SBP is ≥90 and ≤160 mmHg and resting HR is ≥50 and ≤100 bpm (≤110 bpm for atrial fibrillation)\n4. PASP (RVSP) is ≥30 mmHg on the baseline TTE.\n5. Subject has New York Heart Association (NYHA) class II, III or IVa symptoms (IVa is defined as symptoms with minimal exertion or at rest, but the patient is able to ambulate and does not require continuous intravenous medications).\n6. Subject has 6MWD at baseline ranging from 100 to 450 m limited by dyspnea or fatigue and not orthopedic or other non-HF-related issues\n7. Subject has NT-proBNP ≥600 pg\u002FmL for patients with LVEF ≤40% or ≥200 pg\u002FmL for patients with LVEF \\>40% at the time of screening (a central lab will be made available for sites that cannot measure NT-proBNP)\n8. Subject is able and willing to follow all aspects of the research protocol including medication compliance and follow-up visits and testing.\n9. Subject or the subject's legally designated representative signs an IRB\u002FEC approved informed consent form prior to study participation.\n\nExclusion Criteria:\n\n1. Subject has a life expectancy of less than 1 year due to non-cardiovascular causes.\n2. Subject has known hypertrophic cardiomyopathy with either left ventricular (LV) outflow tract obstruction or systolic anterior motion (SAM) of the anterior leaflet of the mitral valve; pericardial disease; or infiltrative or active inflammatory myocardial disease, including known amyloidosis\n3. Subject has severe stenosis or regurgitation of any heart valve, moderate or severe stenosis of the aortic valve, or any degree of stenosis of the pulmonic valve\n4. Subject has symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke in the prior 30 days or any prior stroke with a permanent residual deficit with modified Rankin Scale (mRS) score ≥4\n5. Subject has any prior intracranial hemorrhage with or without a residual deficit, or any known intracranial pathology pre-disposing to bleeding (e.g. mass, AV fistula, aneurysm, etc.)\n6. Subjects with a known bleeding diathesis or who will refuse blood transfusions\n7. Subjects allergic to heparin (including heparin induced thrombocytopenia), unless bivalirudin or argatroban can be used for procedural anticoagulation\n8. Subjects with life threatening allergy to contrast dye that cannot be adequately pre-medicated, or any prior contrast-related anaphylaxis\n9. Subject has congenital heart disease other than mitral valve prolapse or a PFO\n10. Subject had coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the prior 6 months or is anticipated to undergo CABG or PCI within 12 months after randomization.\n11. Subject has any pacemaker with an intracardiac sensing or pacing lead or wire implanted in the prior 3 months, or CardioMEMS HF System or other intracardiac pressure monitoring system, or cardiac contractility modulation system or baroreceptor activation therapy implanted within the prior 3 months, or any plans to implant any of these devices within 12 months after the procedure.\n12. Subject has undergone atrial fibrillation ablation within the prior 6 months or is anticipated to undergo atrial fibrillation ablation within 12 months after randomization.\n13. Subject has undergone heart valve surgery or transcatheter valve intervention within the prior 6 months or is anticipated to undergo heart valve surgery or transcatheter valve intervention (e.g., valve repair or replacement, valvuloplasty) within 12 months after randomization.\n14. Subject has any tricuspid or pulmonic valve implants (implanted annuloplasty rings are allowed).\n15. Subject has an inferior vena cava (IVC) filter implant.\n16. Subject has received a prior heart or heart-lung transplantation or is listed for heart or heart-lung transplantation or is anticipated to receive a ventricular assist device (VAD) implant within 6 months after randomization.\n17. Subjects with intracardiac thrombus on TTE.\n18. Subjects with pericardial effusion ≥10 mm on TTE\n19. Subject's PH is predominantly due to WHO Group 1, 3, 4, or 5. Note: Multifactorial features of PH may be present, but the predominant diagnosis must be WHO Group 2 CpcPH.\n20. Subject has been treated with any group 1 PAH-targeted drugs, including sotatercept, within the prior month or is planned to receive such therapy after randomization.\n21. Subject is anticipated to undergo any surgery within 6 months after randomization (other than minor surgeries requiring only local anesthesia).\n22. Subject has severe renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2 by the CKD-EPI formula, or on dialysis).\n23. Subject has severe liver insufficiency (Child-Pugh classification C).\n24. Subject has platelet count \\\u003C100 × 109\u002FL.\n25. Subject has systemic inflammatory or other disease requiring long-term use of oral glucocorticoids or immunosuppressants.\n26. Subject has active infection requiring oral or intravenous antibiotics.\n27. Subject has a body mass index (BMI) \\>45 kg\u002Fm².\n28. Subjects with severe respiratory disease, defined as any disorder of the respiratory system with diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C40% AND total lung capacity (TLC) \\\u003C60% AND forced expiratory volume in one second (FEV1) \\\u003C70% by plethysmography; OR who require ambulatory or long-term oxygen therapy\n29. Subject has known severe untreated sleep apnea. Note: Subjects with sleep apnea treated with CPAP\u002FBiPAP for at least the prior 3 months are not excluded.\n30. Subjects with pulmonary embolism or deep vein thrombosis in the prior 6 months.\n31. Subject is a pregnant or breastfeeding woman, or a woman planning to become pregnant within one year. Women of child-bearing potential must have a negative pregnancy test within 1 week of randomization.\n32. Subject is participating in another clinical trial of an investigational drug or device that has not reached its primary endpoint.\n33. Subject has severe cachexia\u002Ffrailty, substance abuse, or any other condition that the investigator believes may affect the subject's ability to comply with or complete all the study requirements including follow-up visits.\n34. Subject is a member of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, children, impoverished persons, persons in prisons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations may also include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.",{"count":630,"type":21},750,[93],"The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease (LHD). This randomized control trial will compare the investigational device (The Enhancor System) to control (medical therapy.)\n\nParticipants who will consist of patients with chronic heart failure (HF) who are receiving maximally tolerated guideline-directed medical therapy (GDMT) for left heart failure, are clinically stable, and who have been diagnosed with CpcPH by right heart catheterization (RHC), will be treated with PADN and followed for 3 years.",[522,634,96,27,72,583,635,636],"Heart Failure With Reduced Ejection Fraction","Heart Failure With Preserved Ejection Fraction","Heart Failure With Mid Range Ejection Fraction",[638,639,583,640,641],"Pulmonary Artery Denervation","Pulmonary Hypertension Due to Left Heart Disease","pulmonary hypertension","left heart failure","2026-03-11",{"date":644,"type":39},"2026-03-12",{"date":646,"type":21},"2026-04-01",{"date":648,"type":21},"2031-12-31",{"name":650,"class":108},"Pulnovo Medical, Inc.",{"id":652,"slug":4,"hasResults":11,"nctId":653,"briefTitle":654,"officialTitle":654,"acronym":4,"eligibilityCriteria":655,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":91,"phases":658,"briefSummary":659,"conditions":660,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":47},"100625782","NCT07427108","Road Mapping Guided Puncture Versus Ultrasound Guided Puncture During Retrograde Angioplasty Feasibility and Safety","Inclusion criteria: -.\n\n1. Adults : Both male and female participants.\n2. Diagnosed with critical limp threatening ischemia (CLTI):\n\n   significant occlusions in the femoropopliteal\n\n   o Rutherford Class 5: Non-healing wounds or ulcers\n3. Failed or unable to achieve antegrade access:\n\n   Patients requiring retrograde puncture for the procedure.\n4. Planned intervention with retrograde access: Candidates for endovascular interventions, including angioplasty, stent deployment\n\nExclusion criteria:\n\n• Active infection at the puncture site: Any localized infection, particularly over the ankle region , will be an exclusion.\n\n• Severe calcification or anatomical abnormalities: Patients with excessive arterial calcification or significant anatomical distortion preventing safe retrograde puncture.",{"count":657,"type":21},32,[93],"The study aims to compare the technical feasibility and safety of road mapping-guided versus ultrasound-guided retrograde arterial puncture in patients with (CLTI) as measured by:\n\n* Puncture success rate\n* Access-related complication rate (e.g., hematoma, vessel dissection, perforation)",[606,27],"2026-02-15",{"date":663,"type":39},"2026-02-23",{"date":665,"type":39},"2026-02-01",{"date":667,"type":21},"2027-03-01",{"name":669,"class":173},"Sohag University",""]